VECT VectivBio Holding AG

3.86
-0.11  -3%
Previous Close 3.97
Open 3.84
52 Week Low 3.68
52 Week High 37.6999
Market Cap $138,426,810
Shares 35,861,868
Float 23,920,345
Enterprise Value $-2,139,385
Volume 44,793
Av. Daily Volume 39,680
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Apraglutide - STARS Nutrition
Short bowel syndrome - colon-in-continuity
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Apraglutide - STARGAZE
Acute Graft-Versus-Host Disease
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Apraglutide (STARS)
Short Bowel Syndrome
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. -Pivotal STARS Program of Apraglutide in SBS-IF Progressing with Majority of Sites Activated and Screening; STARS Nutrition Interim Results Expected 1H 2022-

    -Expanded Rare Disease Pipeline with the Acquisition of CoMET Small Molecule Platform for Inherited Metabolic Diseases (IMDs)-

    -IND Application for Apraglutide for Acute Graft-Versus-Host Disease (aGVHD) Cleared by FDA; First Patient in Expected 1Q 2022, Interim Data Expected 2H 2022-

    BASEL, Switzerland, Nov. 10, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today provided a business update for the third quarter ended September…

    -Pivotal STARS Program of Apraglutide in SBS-IF Progressing with Majority of Sites Activated and Screening; STARS Nutrition Interim Results Expected 1H 2022-

    -Expanded Rare Disease Pipeline with the Acquisition of CoMET Small Molecule Platform for Inherited Metabolic Diseases (IMDs)-

    -IND Application for Apraglutide for Acute Graft-Versus-Host Disease (aGVHD) Cleared by FDA; First Patient in Expected 1Q 2022, Interim Data Expected 2H 2022-

    BASEL, Switzerland, Nov. 10, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today provided a business update for the third quarter ended September 30, 2021.

    "VectivBio made tremendous progress this quarter, including the achievement of key milestones and strategic advancements that have expanded the breadth of our efforts to transform the treatment of rare conditions," said Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio. "In October, the FDA cleared our IND to initiate STARGAZE, a Phase 2 trial evaluating apraglutide for the treatment of aGVHD, the second indication for our lead candidate. We expect the first patient to enter this trial during the first quarter of next year and expect initial interim data in the second half of 2022. Notably, this follows successful initiations earlier this year of our pivotal program of apraglutide in patients with short bowel syndrome with intestinal failure (SBS-IF), encompassing the Phase 3 STARS study and the Colon-in-Continuity (CIC) focused STARS Nutrition study. We're happy to report that the Phase 3 Trial is steadily progressing, with the majority of sites activated and screening. We also expect to announce interim results for the STARS Nutrition study in the first half of 2022. These results aim to provide clinically meaningful evidence that apraglutide can improve intestinal absorption and reduce parenteral support volume in CIC patients who represent the majority of SBS and respond poorly to current standard-of-care GLP-2 treatment."

    Dr. Santarelli continued, "Additionally, in September, we acquired CoMET, a modular platform to develop small molecules addressing the deficit of Coenzyme A-mediated energy metabolism that underlies often-fatal and currently intractable inherited metabolic diseases. With this transaction, we have immediately added four new programs to our R&D pipeline and laid a foundation supporting our vision to become a fully integrated rare disease company."

    Third Quarter 2021 and Recent Business Updates

    Apraglutide: Next-generation, long-acting synthetic GLP-2 analog being developed for a range of rare gastrointestinal diseases where GLP-2 can play a central role in addressing disease pathophysiology, including short bowel syndrome with intestinal failure (SBS-IF) and Acute Graft-Versus-Host Disease (aGVHD).

    Apraglutide for SBS-IF:

    • Enrollment is ongoing in STARS (STudy of ApRaglutide in SBS), a pivotal Phase 3 trial of apraglutide for SBS-IF. The global trial, which represents the largest Phase 3 trial ever conducted in SBS-IF, is designed to evaluate once-weekly dosing of apraglutide and accounts for patients' remnant bowel anatomy and individual caloric needs when adapting parenteral support across patient subtypes. The Company expects to report topline data in the second half of 2023.
    • In July, the Company initiated STARS Extend study. Emerging real-world evidence suggests that SBS-IF patients may benefit from longer treatment duration with meaningful reductions in number of days of parenteral support (PS) per week or the ability to completely wean off PS. STARS Extend is an open-label extension trial to evaluate the long-term safety and efficacy of apraglutide in SBS-IF for up to 104 weeks.
    • In June, VectivBio initiated STARS Nutrition, a multicenter, open-label metabolic balance study of apraglutide designed to evaluate the efficacy of once-weekly apraglutide in increasing intestinal energy absorption and reducing the parenteral support requirement in patients with SBS-IF and Colon-in-Continuity (CIC). CIC patients represent over half of the total SBS-IF patients and are underserved by current treatment options. The Company is on track to report interim results in the first half of 2022.

    Apraglutide for aGVHD:

    • In October, VectivBio announced that the U.S. Food and Drug Administration (FDA) cleared the Company's Investigational New Drug (IND) application to evaluate apraglutide in a Phase 2 clinical trial, STARGAZE (Study of Apraglutide in Graft-Versus-Host Disease). VectivBio expects the first patient to enter this trial during the first quarter of 2022, with interim data expected in the second half of 2022. Apraglutide previously received orphan drug designation by the FDA for the prevention of aGVHD in June 2021.

    CoMET Platform: Modular, small molecule platform applying innovative chemistry to address severe Inherited Metabolic Diseases (IMDs) in pediatric populations with a deficit of energy metabolism caused by the depletion of functional Coenzyme A ("CoA").

    • In September, VectivBio successfully acquired Comet Therapeutics, Inc., a privately held company developing drugs to address previously untreatable IMDs. The CoMET platform expands VectivBio's pipeline with the immediate addition of four programs targeting organic acidemias, urea cycle disorders, fatty acid oxidation disorders and amino acidopathies.
    • VectivBio plans to initiate a first-in-human trial of VB-1197, the first candidate from the CoMET platform, in 1Q 2023. VB-1197 will initially being evaluated for the treatment of methylmalonic acidemia (MMA) and propionic acidemia (PA).

    Corporate Updates:

    • In September, the Company announced the appointment of Scott Applebaum as Chief Legal Officer & Corporate Secretary. Mr. Applebaum brings over two decades of legal, regulatory and operational experience in the biopharmaceutical industry to VectivBio. Mr. Applebaum has extensive experience with rare diseases, and spent 10 years at Shire Pharmaceuticals in various senior management roles. Most recently he was the Chief Legal & Compliance Officer and Senior Vice President of Regulatory Affairs at Trevena, where he played a key role in gaining FDA approval for their lead product, Olinvyk®.
    • In September, VectivBio announced the election of Paul R. Carter and Dr. Murray W. Stewart to the Company's Board of Directors as Independent Non-Executive Directors. Most recently, Mr. Carter served as Executive Vice President of Commercial Operations at Gilead where he led launch and commercialization efforts globally. Dr. Stewart is the Chief Medical Officer of Rhythm Pharmaceuticals, a biopharmaceutical company focused on the treatment of rare genetic disorders of obesity, and guided Imcivree® to FDA approval in November 2020. Paul and Murray are expected to play a prominent role in guiding VectivBio in its preparation for the potential approval and commercialization of apraglutide.

    About VectivBio AG



    VectivBio (NASDAQ:VECT) is a global clinical-stage biotechnology company focused on transforming and improving the lives of patients with severe rare conditions. Our lead product candidate, apraglutide, is a next-generation GLP-2 analog currently in a global Phase 3 clinical trial for short bowel syndrome with intestinal failure (SBS-IF). It is being developed for a range of rare gastrointestinal diseases where GLP-2 can play a central role in addressing disease pathophysiology, including Acute Graft-Versus-Host Disease (aGVHD).

    With the CoMET platform, we also aim to address severe and often fatal Inherited Metabolic Diseases (IMDs) in pediatric populations. IMDs represent a group of genetic disorders in which dysregulated Co-enzyme A (CoA) metabolism is a key pathophysiological defect. Candidates from the CoMET platform are initially being evaluated in methylmalonic acidemia (MMA) and propionic acidemia (PA). Additional targets include urea cycle disorders, fatty acid oxidation disorders, and amino acidopathies.

    Learn more at www.vectivbio.com, and follow us on LinkedIn and Twitter.

    VectivBio Contacts:

    Investors:

    Investor Relations

    Media:

    Morgan Warners

    Finsbury Glover Hering

    +1 (202) 295-0124

     



    Primary Logo

    View Full Article Hide Full Article
  2. BASEL, Switzerland, Nov. 04, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will participate in a virtual fireside chat at the Credit Suisse 30th Annual Healthcare Conference on Thursday, November 11, 2021 at 9:40 a.m. ET.

    A live webcast of the fireside chat will be accessible through the Events and Presentations section of VectivBio's website at www.vectivbio.com. An archived replay of the webcast will be available for 30 days following the presentation.

    About VectivBio AG

    VectivBio (NASDAQ:VECT

    BASEL, Switzerland, Nov. 04, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will participate in a virtual fireside chat at the Credit Suisse 30th Annual Healthcare Conference on Thursday, November 11, 2021 at 9:40 a.m. ET.

    A live webcast of the fireside chat will be accessible through the Events and Presentations section of VectivBio's website at www.vectivbio.com. An archived replay of the webcast will be available for 30 days following the presentation.

    About VectivBio AG

    VectivBio (NASDAQ:VECT) is a global clinical-stage biotechnology company focused on transforming and improving the lives of patients with severe rare conditions. Our lead product candidate, apraglutide, is a next-generation GLP-2 analog currently in a global Phase 3 clinical trial for short bowel syndrome with intestinal failure (SBS-IF). It is being developed for a range of rare gastrointestinal diseases where GLP-2 plays a central role in disease pathophysiology, including Acute Graft-Versus-Host Disease (aGVHD).

    With the CoMET platform, we also aim to address severe and often fatal Inherited Metabolic Diseases (IMDs) in pediatric populations. IMDs represent a group of genetic disorders in which dysregulated Co-enzyme A (CoA) metabolism is a factor. Candidates from the CoMET platform are initially being evaluated in methylmalonic acidemia (MMA) and propionic acidemia (PA). Additional targets include urea cycle disorders, fatty acid oxidation disorders, and amino acidopathies.

    Learn more at www.vectivbio.com, and follow us on LinkedIn and Twitter.

    VectivBio Contacts:

    Investors:

    Investor Relations

    Media:

    Morgan Warners

    Finsbury Glover Hering

    +1 (202) 295-0124



    Primary Logo

    View Full Article Hide Full Article
  3. -FDA clears IND Application for Apraglutide for Acute Graft-Versus-Host Disease

    - Dosing of first patient expected in 1Q 2022 -

    - Interim data anticipated in 2H 2022 -

    - FDA previously granted orphan drug designation for apraglutide for the prevention of acute graft-versus-host disease -

    BASEL, Switzerland, Oct. 20, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application to evaluate apraglutide, a next-generation, long-acting GLP-2 analog, in a Phase 2 clinical trial called…

    -FDA clears IND Application for Apraglutide for Acute Graft-Versus-Host Disease

    - Dosing of first patient expected in 1Q 2022 -

    - Interim data anticipated in 2H 2022 -

    - FDA previously granted orphan drug designation for apraglutide for the prevention of acute graft-versus-host disease -

    BASEL, Switzerland, Oct. 20, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application to evaluate apraglutide, a next-generation, long-acting GLP-2 analog, in a Phase 2 clinical trial called STARGAZE (Study of Apraglutide in Graft-Versus-Host Disease), for the treatment of steroid-refractory acute graft-versus-host disease (aGVHD).

    Apraglutide previously received orphan drug designation by the FDA for the prevention of aGVHD in June.

    "Acute graft-versus-host disease typically emerges within the first 100 days after a hematopoietic stem cell transplant and is associated with a high mortality rate," said Omar Khwaja, M.D., Ph.D., Chief Medical Officer of VectivBio. "We have demonstrated promising preclinical results with apraglutide as a novel approach to treating acute graft-versus-host disease, showing a significant reduction in mortality after treatment with apraglutide in mouse models. We are encouraged by this preliminary data and look forward to dosing the first patient in a Phase 2 clinical trial in 1Q 2022."

    "Despite significant advances in managing steroid-refractory graft-versus-host disease, there still remains a high unmet need to develop non-immunosuppressive treatment options specifically targeting the GI tract, one of the primary tissue systems damaged in acute graft-versus-host disease," said Prof. Robert Zeiser, Head of Tumor Immunology and Immune Modulation at the University Medical Center Freiburg. "I believe that apraglutide represents a potentially transformative new therapeutic option for acute graft-versus-host disease patients thanks to its GLP-2 receptor mediated effects on protecting and regenerating Paneth cells and intestinal stem cells."

    STARGAZE, a Phase 2, randomized, double-blind study, will assess the safety, tolerability, pharmacokinetic profile and efficacy of apraglutide in patients with steroid-refractory aGVHD. Dosing of the first patient is expected in 1Q 2022. Interim data read out is anticipated for 2H 2022.

    About aGVHD

    Acute Graft Versus Host Disease (aGVHD) is a severe, rare condition which occurs when immune cells from the donor attack a recipient's healthy cells after an allogeneic hematopoietic stem cell transplant (HSCT). HSCT is standard last-line treatment for many forms of cancer. aGVHD typically emerges within the first 100 days post-transplant and predominantly affects the skin, gastrointestinal (GI) tract and liver. GI GVHD is one of the leading causes of morbidity and mortality following HSCT. More than 22,000 allogeneic HSCTs take place in the U.S. and Europe annually and aGVHD occurs in an estimated 30-50% of patients. Corticosteroids are the first line standard of care for aGVHD, but approximately half of patients will become steroid-refractory. Mortality of 30% at 12-months in steroid-refractory aGVHD patients is driven by the severity of GI symptoms, with grades II, III, and IV having ~80%, ~25%, and ~5% survival rates, respectively.

    About Apraglutide

    Apraglutide is a next-generation, long-acting, potent, synthetic GLP-2 analog that acts as a selective, full agonist of the GLP-2 receptor. It is an investigational new drug that is currently being evaluated in a pivotal phase 3 clinical trial for patients who have short bowel syndrome with intestinal failure (SBS-IF). Patients with SBS-IF require parenteral support (PS), the intravenous delivery of essential fluids and nutrients, to survive. Apraglutide is designed to enable patients to minimize the burden from PS by increasing intestinal absorption of fluids, calories and nutrients. Based on preclinical and clinical data to date, apraglutide has the potential to advance the treatment of SBS-IF by establishing less frequent dosing and improving outcomes in a clinically meaningful fashion to address the needs of patients across the anatomical spectrum that characterizes the disease. Apraglutide is also being evaluated in steroid-refractory acute graft-versus-host disease (aGVHD) and has demonstrated improvements in survival in pre-clinical aGVHD models. VectivBio anticipates dosing the first patient in a Phase 2 clinical trial of apraglutide for aGVHD in the first quarter of 2022 with interim data expected in the second half of 2022.



    About VectivBio AG

    VectivBio (NASDAQ:VECT) is a global clinical-stage biotechnology company focused on transforming and improving the lives of patients with severe rare conditions. Our lead product candidate, apraglutide, is a next-generation GLP-2 analog currently in a global Phase 3 clinical trial for short bowel syndrome with intestinal failure (SBS-IF). It is being developed for a range of rare gastrointestinal diseases where GLP-2 plays a central role in disease pathophysiology, including Acute Graft-Versus-Host Disease (aGVHD).

    With the CoMET platform, we also aim to address severe and often fatal Inherited Metabolic Diseases (IMDs) in pediatric populations. IMDs represent a group of genetic disorders in which dysregulated Co-enzyme A (CoA) metabolism is a factor. Candidates from the CoMET platform are initially being evaluated in methylmalonic acidemia (MMA) and propionic acidemia (PA). Additional targets include urea cycle disorders, fatty acid oxidation disorders, and amino acidopathies.

    Learn more at www.vectivbio.com, and follow us on LinkedIn and Twitter.

    Forward Looking Statements



    Forward-looking statements are statements that are not historical facts. Words and phrases such as "anticipated," "forward," "will," "would," "may," "remain," "potential," "prepare," "expected," "believe," "plan," "near future," "belief," "guidance," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements concerning the acquisition of Comet Therapeutics and the prospects of its platform, the success of development and commercialization efforts with respect to VectivBio's product candidate and VectivBio's plans to initiate additional clinical studies of apraglutide and to expand its rare disease product portfolio. All of such statements are subject to risks and uncertainties, many of which are difficult to predict and generally beyond VectivBio's control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. Such risks and uncertainties include, but are not limited to: the impacts of the ongoing COVID-19 pandemic, including interruptions or other adverse effects on clinical trials and delays in regulatory review; delay in or failure to obtain regulatory approval of VectivBio's product candidate and successful compliance with FDA and other governmental regulations applicable to product approvals; the risks inherent in drug development and in conducting clinical trials; and those risks and uncertainties identified in the "Risk Factors" section of VectivBio's Registration Statement on Form F-1 declared effective by the Securities and Exchange Commission on April 8, 2021 and its other subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, VectivBio undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    Investors

    Claudia D'Augusta

    Media

    Morgan Warners

    +1 (202) 295-0124



    Primary Logo

    View Full Article Hide Full Article
  4. BASEL, Switzerland, Sept. 21, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the closing of its previously announced acquisition of Comet Therapeutics, Inc., a privately held company that has been developing drugs to address previously untreatable Inherited Metabolic Diseases (IMDs). Omar Khwaja, M.D., Ph.D., Chief Medical Officer of VectivBio, will present the CoMET platform at today's VectivBio R&D Day, 10 a.m. – 12 p.m. EDT, that can be accessed by visiting the "Events & Presentations" section of VectivBio's website.

    The CoMET small molecule platform aims to treat a large group…

    BASEL, Switzerland, Sept. 21, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the closing of its previously announced acquisition of Comet Therapeutics, Inc., a privately held company that has been developing drugs to address previously untreatable Inherited Metabolic Diseases (IMDs). Omar Khwaja, M.D., Ph.D., Chief Medical Officer of VectivBio, will present the CoMET platform at today's VectivBio R&D Day, 10 a.m. – 12 p.m. EDT, that can be accessed by visiting the "Events & Presentations" section of VectivBio's website.

    The CoMET small molecule platform aims to treat a large group of life-threatening IMDs, which are severe genetic disorders caused by congenital defects of metabolism fundamental to energy generation and the survival of cells. While each IMD is individually rare, collectively, they occur in 1 in 800 births, affect over 75,000 people in the United States and Europe, and are one of the leading causes of death from non-acquired causes in children.

    The genetic defects causing IMDs disrupt energy production, promote the accumulation of toxic metabolites, and result in the dysregulation of Co-enzyme A (CoA), a core component of many metabolic pathways. The CoMET platform is designed to target these critical cellular dysfunctions by utilizing a stabilized CoA precursor backbone to supply functional CoA and carry tailored intermediary metabolite cargos to address specific underlying conditions. This modular technology can potentially treat multiple previously untreatable IMDs by systemically and intracellularly delivering medicines that restore cellular function.

    The acquisition of the CoMET platform significantly enhances and expands VectivBio's pipeline with the immediate addition of 4 programs targeting organic acidemias, urea cycle disorders, fatty acid oxidation disorders, and amino acidopathies. The first candidate from the CoMET platform, VB-1197, is initially being evaluated in methylmalonic acidemia (MMA) and propionic acidemia (PA), two organic acidemias that have a mortality rate of up to 40% in patients by 18 years old and result in severe neurological disability in adult survivors. The Phase 1 trial is expected to commence within the next 18 months.

    About VectivBio AG

    VectivBio (NASDAQ:VECT) is a global, clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions with high unmet medical need. VectivBio is committed to pursuing product candidates with a clear mechanism of action and the potential to meaningfully transform and improve the lives of patients and their families. VectivBio's product candidate, apraglutide, is a next-generation GLP-2 analog being developed as a differentiated therapeutic for a range of rare gastrointestinal diseases. Apraglutide is currently being evaluated in a global Phase 3 clinical trial as a once-weekly treatment for short bowel syndrome with intestinal failure. VectivBio also plans to initiate clinical studies of apraglutide in additional indications, including graft versus host disease, where GLP-2 is believed to be central to disease pathophysiology.

    Forward Looking Statements

    Forward-looking statements are statements that are not historical facts. Words and phrases such as "anticipated," "forward," "will," "would," "may," "remain," "potential," "prepare," "expected," "believe," "plan," "near future," "belief," "guidance," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements concerning the acquisition of Comet Therapeutics and the prospects of its platform, the success of development and commercialization efforts with respect to VectivBio's product candidate and VectivBio's plans to initiate additional clinical studies of apraglutide and to expand its rare disease product portfolio. All of such statements are subject to risks and uncertainties, many of which are difficult to predict and generally beyond VectivBio's control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. Such risks and uncertainties include, but are not limited to: the impacts of the ongoing COVID-19 pandemic, including interruptions or other adverse effects on clinical trials and delays in regulatory review; delay in or failure to obtain regulatory approval of VectivBio's product candidate and successful compliance with FDA and other governmental regulations applicable to product approvals; the risks inherent in drug development and in conducting clinical trials; and those risks and uncertainties identified in the "Risk Factors" section of VectivBio's Registration Statement on Form F-1 declared effective by the Securities and Exchange Commission on April 8, 2021 and its other subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, VectivBio undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    For more information visit www.vectivbio.com, and follow us on LinkedIn and Twitter.

    Investors

    Graham Morrell

    Media

    Morgan Warners

    +1 (202) 295 0124



    Primary Logo

    View Full Article Hide Full Article
  5. BASEL, Switzerland, Sept. 16, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced upcoming investor events.

    VectivBio R&D Day

    VectivBio will host a virtual R&D Day for analysts and investors on Tuesday, September 21, from 10 a.m. – 12 p.m. EDT.

    The Company will share the progress of its late-stage clinical candidate, apraglutide, a next-generation GLP-2 analog, in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Graft Versus Host Disease (GVHD), as well as present their new CoMET platform for Inherited Metabolic Diseases.

    VectivBio's management team will be joined by KOLs…

    BASEL, Switzerland, Sept. 16, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced upcoming investor events.

    VectivBio R&D Day

    VectivBio will host a virtual R&D Day for analysts and investors on Tuesday, September 21, from 10 a.m. – 12 p.m. EDT.

    The Company will share the progress of its late-stage clinical candidate, apraglutide, a next-generation GLP-2 analog, in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Graft Versus Host Disease (GVHD), as well as present their new CoMET platform for Inherited Metabolic Diseases.

    VectivBio's management team will be joined by KOLs: Dr. Kishore Iyer, Director of Adult and Pediatric Intestinal Rehabilitation & Transplantation at Mount Sinai Medical Center, and Dr. Robert Zeiser, Head of Tumor Immunology and Immune Modulation at the University Medical Center Freiburg, who will discuss the latest research in SBS-IF and GVHD, respectively.

    The webcast can be accessed in the "Events & Presentations" section of VectivBio's website at https://ir.vectivbio.com/events-and-presentations and registration is now open. The presentation and Q&A session can also be accessed by dialing (855) 307-5413 (U.S.) or (929) 517-0945 (International) and entering conference ID: 3579678.

    SVB Leerink CybeRX Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event

    VectivBio's management team will be participating in 1x1 investor meetings at the SVB Leerink CybeRX Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event on Thursday, September 23, 2021. To request a meeting with VectivBio, please contact your SVB Leerink representative.

    About VectivBio AG



    VectivBio (NASDAQ:VECT) is a global, clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions with high unmet medical need. VectivBio is committed to pursuing product candidates with a clear mechanism of action and the potential to meaningfully transform and improve the lives of patients and their families. VectivBio's product candidate, apraglutide, is a next-generation GLP-2 analog being developed as a differentiated therapeutic for a range of rare gastrointestinal diseases. Apraglutide is currently being evaluated in a global Phase 3 clinical trial as a once-weekly treatment for short bowel syndrome with intestinal failure. VectivBio also plans to initiate clinical studies of apraglutide in additional indications, including graft versus host disease, where GLP-2 is believed to be central to disease pathophysiology.

    Forward Looking Statements



    Forward-looking statements are statements that are not historical facts. Words and phrases such as "anticipated," "forward," "will," "would," "may," "remain," "potential," "prepare," "expected," "believe," "plan," "near future," "belief," "guidance," and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties, many of which are difficult to predict and generally beyond VectivBio's control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. Such risks and uncertainties include, but are not limited to: the impacts of the ongoing COVID-19 pandemic and those risks and uncertainties identified in the "Risk Factors" section of VectivBio's Registration Statement on Form F-1 declared effective by the Securities and Exchange Commission on April 8, 2021 and its other subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, VectivBio undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    For more information visit www.vectivbio.com, and follow us on LinkedIn and Twitter.

    Investors

    Graham Morrell

    Media

    Morgan Warners

    +1 (202) 295 0124



    Primary Logo

    View Full Article Hide Full Article
View All VectivBio Holding AG News